844 / 1084
Authors
Patients RT
Chemotherapy
Surgery Outcome
Allal et al.
IJROBP 2005; Ann
Oncol 2003
N=19
T3-4 or N+
Median dose 38.4 Gy
(hyperfx)
2 cycles of Cisplatin (100 mg/m
2
) d1; 5FU
(800 mg/m
2
) d1-4; leucovorin (60 mg bid)
d1-4 Second cycle during RT
D2 with (sub) total
gastric resection
R0 resection 100%
pCR+pPR 47%
2yr OS 71%
Ajani et al.
JCO 2004
N=34
T2-3, Nany or
T1N1
45 Gy/25 fx
2 cycles of Cisplatin (20 mg/m
2
) d 1-5; 5FU
(200 mg/m
2
) 21 days; leucovorin (20 mg
2
)
d1, 8, 15
During RT: 5FU (300 mg/m
2
) dd conti. iv
D2
Median number
lymph nodes
examined: 16
R0 resection 70%
pCR+pPR 54%
2yr OS 54%
Lowy et al.
Ann Surg Oncol 2001
N=24
≥T2 and/or N+
45 Gy/25 fx
10 Gy intra-operative
5FU c.i. (300 mg/m
2
)
83% D2
Rest PD
11% pCR
63% sign treatment effect
Ajani et al.
JCO 2005
N=41
T2-3N0-1
T1N1
45 Gy/25 fx
2 induction courses of fluorouracil,
paclitaxel and cisplatin;
5FU and paclitaxel concurrent with RT
98% S
78% R0
pCR 20%
pPR 15%
Ajani et al.
JCO 2006
N=43 assessable
[20 institutions]
45 Gy/25 fx
2 induction courses with 5FU, leucovorin
and cisplatin; fluorouracil and paclitaxel
50% D2
pCR 26%
R0 77%
Pre-operative chemoradiotherapy: phase I-II studies
T2-3N0-1
or T1N1
concurrent with RT
Med surv 23.2 m
1yr surv 72%
Wydmanski
et al. R&O 2007
N=40
TNM??
45 Gy/25 fx
4 5FU and LV based schedules (1st and
last week of RT)
80% S (D2)
R0 94%
pCR 17.5%
pPR 20%
2yr surv 63%
Saikawa et al.
IJROBP 2008
N=29 evaluable
40 Gy/20 fx
S1 (60 mg/m2/d) and
Cisplatin (6 mg/m
2
/d)
33% S D2;
> 10 months
R0: 100%
pCR: 4/30 (13.3%)
Med surv 25 m
Trip et al. R&O 2014 N=25
II-IV (M0)
45 Gy/25 fx
weekly carboplatin and paclitaxel
concurrent with RT
84% D1+
R0: 72%
pCR: 16%
Combined 19 - 43 pts 40 - 45 Gy 5FU/cis-/carboplatin/
paclitaxel
D2
R0: 70 - 100%
pCR: 11 - 26%
From: Trip et al. Transl Gastrointest Cancer 2015